|
| 抗肿瘤药体外药敏与大肠癌疗效和预后的相关性 |
| Correlation Between in vitro Chemosensitivity of Antineoplastic Drugs and its Clinical Response and Prognosis in Human Colorectai Cancers |
| 投稿时间：2006-09-20 修订日期：2006-12-08 |
| DOI： |
| 中文关键词: 氟尿嘧啶 丝裂霉素 大肠癌 体外药敏 化疗疗效 Cox模型 |
| 英文关键词:MTT |
| 基金项目:上海浦东新区社会发展局医学科研项目 |
| 翟晓波 卢爱国 鲍思蔚 何志高 |
同济大学附属东方医院药剂科 (上海200120)
(翟晓波，鲍思蔚，何志高)
，同济大学附属东方医院普外科 (上海200120)
(卢爱国)
|
| 摘要点击次数: 2664 |
| 全文下载次数: 111 |
| 中文摘要: |
| 目的:探讨氟尿嘧啶(5-Fu)联用丝裂霉素(MMC)治疗大肠癌的体外药敏与临床化疗疗效和预后的相关性。方法:用MTT法测定联合化疗方案5-Fu MMC对169例Dukes B、C期大肠癌的体外敏感性,统计术后4年内复发率和预后。结果:将使用5-Fu、MMC联合化疗的100例,按体外药敏分成拮抗组28例,复发率57．1％;协同、相加组72例,复发率22．2％(P<0．01)。再将这100例分成体外耐药组31例,复发率45．2％;体外敏感组69例,复发率24．6％(P<0．05)。Cox多因素分析显示,体外药敏为拮抗,则死亡相对风险度增加4．56倍。结论:5-Fu、MMC体外发生协同相加、拮抗作用、敏感和耐药,都可以作为预测大肠癌临床化疗疗效的指标,但前者与预后相关,后者不相关。 |
| 英文摘要: |
| Objective:To study the correlation between in vitro chemosensitivity of Fluorouraci(5-Fu) Mitomycia (MMC) and its clinical response and prognosis in human colorectal cancers. Method:The chemosensitivity of 5-Fu MMC was tested in 169 Dukes B and C colorectal cancers with the MTT method,and the progression-free internal and prognosis in 4 years following the surgery were observed. Result:Based on the in vitro chemosensitivity of 5-Fu MMC, 100 patients were divided into an antagonistic group(28 patients) in which their relapse rates were 57. 1% and a synergistic-additive group(72 patients) in which their relapse rates were 22.2% (P<0.01). We divided the same 100 patients into an insensitive group (31 patients) in which their relapse rates were 45.2% and a sensitive group (69 patients) in which their relapse rates were 24.6% (P<0.05). The multivariate analysis indicated that the relative death risk increased by 4.56 times in the case of in vitro antagonism. Conclusion:All the in vitro synergism, addition, antagonism and sensitivity or insensitivity of 5-Fu MMC could acted as the guidelines of chemotherapeutic results in colorectal cancers, but the former was related to the prognosis, and the latter was not. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
